This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) News Today Add Compare Share Share Headlines Stock AnalysisHeadlinesTrendsBuy This Stock TROV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Cardiff Oncology to Host Investor Webcast on June 3 for CRDF-004 Data Update in RAS-Mutated Metastatic Colorectal Cancer TrialMay 21 at 5:31 PM | quiverquant.comQCardiff Oncology to Present Updated Data on Onvansertib in RAS-Mutated Colorectal Cancer at ASCO 2026April 21, 2026 | quiverquant.comQCardiff Oncology Names Interim CEO to Role on Permanent Basis; Appoints CFOApril 9, 2026 | marketwatch.comCardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 19, 2026 | markets.businessinsider.comCardiff Oncology CEO and CFO Step DownJanuary 27, 2026 | marketwatch.comCardiff Oncoolgy Shares Plunge on CFO, CEO ExitsJanuary 27, 2026 | marketwatch.comCardiff Oncology slumps after leadership shakeupJanuary 27, 2026 | msn.comCardiff Oncology initiated with an outperform at Noble CapitalJanuary 5, 2026 | msn.comCardiff Oncology, Inc. to Participate in Piper Sandler 37th Annual Healthcare ConferenceNovember 24, 2025 | quiverquant.comQCardiff Oncology Reports Increased Losses Amid Ongoing TrialsNovember 6, 2025 | tipranks.comCardiff Oncology reports Q3 EPS (17c), consensus (21c)November 6, 2025 | msn.comCardiff Oncology price target lowered to $10 from $18 at H.C. WainwrightAugust 6, 2025 | msn.comCardiff Oncology Shares Fall After Posting Wider 2Q LossJuly 30, 2025 | marketwatch.comJefferies Initiates Coverage of Cardiff Oncology (CRDF) with Hold RecommendationJune 25, 2025 | msn.comCardiff Oncology falls after naming new medical chief ahead of key trial readoutJune 17, 2025 | msn.comCardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + PaclitaxelJune 3, 2025 | insidermonkey.comCardiff Oncology announces second patent for onvansertib combinationApril 24, 2025 | markets.businessinsider.comCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsApril 23, 2025 | tmcnet.comCardiff Oncology (NASDAQ:CRDF) Stock, Option ChainApril 23, 2025 | benzinga.comIs Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5?March 26, 2025 | insidermonkey.comWilliam Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comCardiff Oncology announces positive colorectal data and $40m stock oversubscriptionDecember 11, 2024 | msn.comCardiff stock soars on onvansertib data, $40M direct offeringDecember 10, 2024 | msn.comCardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingDecember 10, 2024 | tmcnet.comCardiff Oncology Reports Positive Q3 2024 Results and Clinical ProgressNovember 9, 2024 | markets.businessinsider.comCardiff Oncology Reports Third Quarter 2024 Results and Provides Business UpdateNovember 8, 2024 | markets.businessinsider.comCardiff Oncology publishes onvansertib combination data in journalNovember 1, 2024 | markets.businessinsider.comCardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC MarketOctober 4, 2024 | seekingalpha.comCraig-Hallum Sticks to Its Buy Rating for Cardiff Oncology (CRDF)September 13, 2024 | markets.businessinsider.comCardiff: Second Half Of 2024 mCRC Data Is Major Inflection PointAugust 12, 2024 | seekingalpha.comCardiff Oncology, Inc. (NASDAQ:CRDF) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | msn.comCRDF Stock Earnings: Cardiff Oncology Misses EPS, Beats Revenue for Q2 2024August 9, 2024 | markets.businessinsider.comCardiff Oncology Reports Second Quarter 2024 Results and Provides Business UpdateAugust 9, 2024 | markets.businessinsider.comCardiff Oncology's Onvansertib: A Speculative Buy With Promising DataMay 22, 2024 | seekingalpha.comBuy Rating Affirmed on Cardiff Oncology as Phase 2 Trial Shows Promise for Accelerated ApprovalMay 7, 2024 | markets.businessinsider.comCardiff Oncology Stock (NASDAQ:CRDF) Dividends: History, Yield and DatesFebruary 23, 2024 | benzinga.comCardiff Oncology’s Onvansertib Shows Promise: An Analysis of the Buy Rating RecommendationSeptember 29, 2023 | markets.businessinsider.comStocks to Watch: MillerKnoll, Cardiff Oncology, Morphic HoldingsSeptember 26, 2023 | marketwatch.comCardiff Oncology Shares Up 26% After Potential Cancer Treatment AdvancesAugust 8, 2023 | marketwatch.comH.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)August 8, 2023 | markets.businessinsider.comCardiff Oncology (NASDAQ: CRDF)May 27, 2023 | fool.comCardiff OncologyJanuary 13, 2023 | forbes.comCardiff Oncology: Staying The CourseDecember 14, 2022 | seekingalpha.comClear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively BuyingOctober 16, 2022 | markets.businessinsider.comCardiff Oncology, Inc. (CRDF)September 29, 2022 | finance.yahoo.comCRDF Cardiff Oncology, Inc.September 24, 2022 | seekingalpha.comLooking Into Cardiff Oncology's Return On Capital EmployedAugust 25, 2022 | msn.comCardiff Oncology: Down But Not OutAugust 22, 2022 | seekingalpha.comCardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?July 28, 2022 | finance.yahoo.com Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TROV Media Mentions By Week TROV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TROV News Sentiment▼0.000.45▲Average Medical News Sentiment TROV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TROV Articles This Week▼10▲TROV Articles Average Week Get the Latest News and Ratings for TROV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cardiff Oncology and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NKGN News Today BLUW News Today PLX News Today FORA News Today BDMD News Today MNOV News Today LFVN News Today LUNG News Today TCRX News Today OKYO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TROV) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
